CD274 and non-small cell lung carcinoma: The year 2020 brought a new Food and Drug Administration (FDA) registration based on CA 209-227 trial—nivolumab combined with ipilimumab was found superior to chemotherapy alone in an untreated NSCLC patient in whom PD-L1 expression was ≥1%.